Drops in the stock price of Keros Therapeutics are typically triggered by common market pressures impacting clinical-stage biotechnology equities, such as investor caution ahead of clinical trial readouts, broader sector sell-offs, or shifts in macroeconomic interest rate environments. Additionally, when biotechnology firms announce secondary public offerings or equity dilution to secure necessary operational capital for upcoming clinical trials, shares frequently experience near-term downward pressure. Because pre-revenue biotech stocks react sensitively to pipeline developments and regulatory updates, any delay or cautious interpretation of clinical data can cause swift share adjustments.